Abstract
Background Wilson disease (WD) causes intracellular copper accumulation in the body due to a genetic defect in the protein ATP7B. Cardiac involvement such as electrocardiographic abnormalities, rhythm abnormalities, heart failure and cardiac death have been reported, however pathophysiological mechanisms remain unclear.
Objectives This study aimed to comprehensively assess the myocardium in WD patients without cardiac symptoms using multiparametric cardiovascular magnetic resonance imaging (CMR), including quantitative stress perfusion mapping and strain analysis.
Methods WD patients (n=17, 41±16 years, 47% female) and volunteers (n=17, 39±15 years, 47% female) underwent multiparametric mapping at 1.5 T CMR including cine, native T1, native T2, adenosine stress perfusion mapping, late gadolinium enhancement (LGE), and extracellular volume (ECV) imaging. Symptoms of myocardial ischemia were quantified using Seattle Angina Questionnaire-7 (SAQ-7) and cardiovascular risk factors and medications were recorded.
Results Both stress perfusion and MPR were lower in WD patients (2.95±0.58 vs 3.67±1.01 ml/min/g, and 3.4±0.8 vs 4.4±1.9), while ECV was higher, (29±3% vs 27±2%), p<0.05 for all. Left ventricular ejection fraction (LVEF) was lower in WD patients, (56±6% vs 61±6%, p=0.02), and LV ventricular global circumferential strain (LV GCS) was higher (-18±2% vs - 20±2%, p=0.005). Late gadolinium enhancement (LGE) was present in the right ventricular insertion point (RVIP) in 12/17 (71%) of the WD patients.
Conclusions In this small mechanistic study, WD patients on stable treatment without apparent cardiac symptoms have early signs of diffuse fibrosis, coronary microvascular dysfunction (CMD) and systolic dysfunction, shedding light on pathophysiological mechanisms of cardiac dysfunction in copper accumulation.
Competing Interest Statement
Previously, Nickander has received minor speaker compensation from Sanofi-Genzyme for work unrelated to the current study. Steffen Johansson and Fogarasi declare no relationships with industry. The Karolinska University Hospital has a research and development agreement with Siemens Healthineers. Kindmark has research grants funded by Sanofi-Genzyme, Takeda, Orphalan, BioMarin and has received consultant or speaker compensation from Amgen, UCB, Sanofi-Genzyme, Takeda, Orphalan, BioMarin, Chiesi, Abacus, and Amicus.
Funding Statement
The study was funded in part by The Swedish Society of Medicine, Tore Nilsson Foundation, Magnus Bergvalls Stiftelse, and Swedish Heart and Lung Foundation. Steffen Johansson is funded by The Swedish Society of Medicine, Swedish Heart and Lung Foundation and the Region of Stockholm, Sweden. Fogarasi is funded by The Swedish Society of Medicine, and Swedish Heart and Lung Foundation. Nickander is funded by Swedish Heart and Lung Foundation and the Region of Stockholm. Kindmark is funded by the Region of Uppsala.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Swedish Ethical Review Authority granted ethical approval for the study (DNR 2019 06287, with amendments 2019 06287, 2021 05508 02, 2022 06995 02 and for volunteers 2015/2106 31/1 and 2014/131 31/1, 2017/2415 32/1, 2021 06837 02)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Upon reasonable request, data supporting the findings in this study are available from the corresponding author.
